CGAS and breast cancer: Conversely, radiotherapy delivered at doses above 12-18 Gy induces Trex1 in other breast cancer models, which can hinder the pro-immune effects of radiotherapy by degrading cellular DNA upstream of the cGAS/STING pathway (177).